retatrutide mechanism of action retatrutide clinical trials Diagram showing the of Retatrutide vs Ozempic: Clinical Trial

Summary: Retatrutide is taken once weekly as a subcutaneous injection, with doses gradually escalated from a low starting dose up to a studied maximum of 12 mg in Phase 2 trials, though it is not yet approved for use in the UK

Full COA available as PDF on this page

STEP 1: Health care provider (HCP) application portion Click here to submit the HCP portion of your patient's application

Clinical studies have consistently demonstrated that higher-dose semaglutide treatments lead to significantly greater weight loss outcomes compared to lower-dose options (such as Ozempic)

Dry Mouth (Xerostomia): When Your Mouths Natural Shield Disappears Think of saliva as your mouths built-in mouthwash

Crystal Beal